Japan’s MHLW authorises Regeneron and Sanofi’s Dupixent for COPD
This new option is intended for patients whose COPD is not sufficiently controlled with existing treatment. COPD is a chronic respiratory disease that progressively impairs lung function and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.